Why do exceptional survivors hold the blueprint to defeating cancer?

Why do exceptional survivors hold the blueprint to defeating cancer?

The science

Rosalind Study

Publication Date:

Why do exceptional survivors hold the blueprint to defeating cancer? Because they already have.
We have analyzed over 1,000 exceptional survivors to reveal novel therapeutic targets and provide strong validation of our approach.

📹 Watch the video to see how we're turning the biology of exceptional cancer survivors into the next generation of cancer medicines. Until All Survive.


Updated: June 23, 2026

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.